*Naoto KAJITANI1,2,3, Mami OKADA-TSUCHIOKA3, Asuka INOUE4, Kanako MIYANO5,6, Takeshi MASUDA7, Shuken BOKU1, Kazuya IWAMOTO8, Sumio OHTSUKI7, Yasuhito UEZONO5, Junken AOKI9, Minoru TAKEBAYASHI1,3
(1. Department of Neuropsychiatry, Faculty of Life Sciences, Kumamoto University, 2. Center for Metabolic Regulation of Healthy Aging, Faculty of Life Sciences, Kumamoto University, 3. Division of Psychiatry and Neuroscience, Institute for Clinical Research, National Hospital Organization Kure Medical Center, 4. Laboratory of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, 5. Department of Pain Control Research, The Jikei University School of Medicine, 6. Division of Cancer Pathophysiology, National Cancer Center Research Institute, 7. Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, 8. Department of Molecular Brain Science, Graduate School of Medical Sciences, Kumamoto University, 9. Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo)
Keywords:Antidepressant, Lysophosphatidic acid, Biased agonist
Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.